Kazan Federal University Digital Repository

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

Show simple item record

dc.contributor.author Arora S.
dc.contributor.author Velichinskii R.
dc.contributor.author Lesh R.
dc.contributor.author Ali U.
dc.contributor.author Kubiak M.
dc.contributor.author Bansal P.
dc.contributor.author Borghaei H.
dc.contributor.author Edelman M.
dc.contributor.author Boumber Y.
dc.date.accessioned 2020-01-21T20:38:10Z
dc.date.available 2020-01-21T20:38:10Z
dc.date.issued 2019
dc.identifier.issn 0741-238X
dc.identifier.uri https://dspace.kpfu.ru/xmlui/handle/net/157515
dc.description.abstract © 2019, The Author(s). In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival benefit has been experienced by many cancer patients, with favorable toxicity profiles of immunotherapeutic agents relative to chemotherapy. Cures have become possible in some patients with metastatic disease. Additional approvals of immunotherapy drugs and in combination with other agents are anticipated in the near future. Multiple additional immunotherapy drugs are in earlier stages of clinical development, and their testing in additional tumor types is under way. Despite considerable early success and relatively fewer side effects, the majority of cancer patients do not respond to checkpoint inhibitors. Additionally, while the drugs are generally well tolerated, there is still the potential for significant, unpredictable and even fatal toxicity with these agents. Improved biomarkers may help to better select patients who are more likely to respond to these drugs. Two key biologically important predictive tissue biomarkers, specifically, PD-L1 and mismatch repair deficiency, have been FDA-approved in conjunction with the checkpoint inhibitor, pembrolizumab. Tumor mutation burden, another promising biomarker, is emerging in several tumor types, and may also soon receive approval. Finally, several other tissue and liquid biomarkers are emerging that could help guide single-agent immunotherapy and in combination with other agents. Of these, one promising investigational biomarker is alteration or deficiency in DNA damage response (DDR) pathways, with altered DDR observed in a broad spectrum of tumors. Here, we provide a critical overview of current, emerging, and investigational biomarkers in the context of response to immunotherapy in solid tumors.
dc.relation.ispartofseries Advances in Therapy
dc.subject Biomarkers
dc.subject Cytotoxic T-lymphocyte antigen 4 (CTLA-4)
dc.subject DNA damage response (DDR)
dc.subject Immunotherapy
dc.subject Mismatch repair deficiency (MMR)
dc.subject Programmed death 1 (PD-1)
dc.subject Tumor mutation burden (TMB)
dc.title Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
dc.type Review
dc.relation.ispartofseries-issue 10
dc.relation.ispartofseries-volume 36
dc.collection Публикации сотрудников КФУ
dc.relation.startpage 2638
dc.source.id SCOPUS0741238X-2019-36-10-SID85071013125


Files in this item

This item appears in the following Collection(s)

  • Публикации сотрудников КФУ Scopus [24551]
    Коллекция содержит публикации сотрудников Казанского федерального (до 2010 года Казанского государственного) университета, проиндексированные в БД Scopus, начиная с 1970г.

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics